The International Journal of Neuropsychopharmacology
November 15, 2017
Kai Zhang, Chao Dong, Yuko Fujita et al.
48 citations
Background: Previous reports suggest that 5-hydroxytryptamine might play a role in the antidepressant actions of (R,S)-ketamine. However, its role in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, is unknown. This study was conducted to examine whether 5-hydroxytryptamine depletion affects the antidepressant actions of (R)-ketamine in a chronic social defeat...
The International Journal of Neuropsychopharmacology
November 14, 2017
Yukihiko Shirayama, Kenji Hashimoto
113 citations
Background: (R)-Ketamine exhibits rapid and sustained antidepressant effects in animal models of depression. It is stereoselectively metabolized to (R)-norketamine and subsequently to (2R,6R)-hydroxynorketamine in the liver. The metabolism of ketamine to hydroxynorketamine was recently demonstrated to be essential for ketamine's antidepressant actions. However, no study has compared the...
Scientific Reports
November 10, 2017
Youge Qu, Chun Yang, Qian Ren et al.
126 citations
Accumulating evidence suggests a key role of the gut-microbiota-brain axis in the antidepressant actions of certain compounds. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, showed rapid and sustained antidepressant effects in treatment-resistant depressed patients. In contrast, another NMDAR antagonist, lanicemine, did not exhibit antidepressant effects in such patients....
Magnetic resonance imaging
November 2017
Jia-Sheng Rao, Zuxiang Liu, Can Zhao et al.
Ketamine is a well-known anesthetic. 'Recreational' use of ketamine common induces psychosis-like symptoms and cognitive impairments. The acute and chronic effects of ketamine on relevant brain circuits have been studied, but the effects of single-dose ketamine administration on the local resting-state functional properties of the brain remain unknown. In this study, we aimed to assess the...
American Journal of Geriatric Psychiatry
November 2017
Duncan George, Verònica Gálvez, Donel Martin et al.
To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-resistant depression. Secondary aims were to examine if repeated treatments were safe and more effective in inducing or prolonging remission than a single treatment. In this double-blind, controlled, multiple-crossover study with a 6-month follow-up (randomized controlled trial [RCT] phase), 16 participants (≥60...
Military Medicine
October 31, 2017
Madeleine Baldwin, Henry Boilini, Georgine Lamvu
7 citations
In the United States, the suicide rate is climbing and was reported at 13 per 100,000, the highest in 28 years. 1 Suicide is now considered as the 10th leading cause of death, and the rate has been increasing every year from 2000 to 2014 among both women and men and in every age group except those 75 and older. 1 The suicide rate among the veteran population is reportedly higher than the...
PLoS One
October 26, 2017
Grace E. Fox, Meng Li, Fang Zhao et al.
Ketamine is known to induce psychotic-like symptoms, including delirium and visual hallucinations. It also causes neuronal damage and cell death in the retrosplenial cortex (RSC), an area that is thought to be a part of high visual cortical pathways and at least partially responsible for ketamine’s psychotomimetic activities. However, the basic physiological properties of RSC cells as well as...
Journal of Psychopharmacology
October 17, 2017
Mark J. Niciu, Nicolas D. Iadarola, Dipavo Banerjee et al.
23 citations
BACKGROUND: This study sought to reproduce, in a larger sample, previous findings of a correlation between smaller raw 3-Tesla (3T) hippocampal volumes and improved antidepressant efficacy of ketamine in individuals with major depressive disorder (MDD). A secondary analysis stratified subjects according to functional BDNF rs6265 (val66met) genotype. METHODS: Unmedicated subjects with...
Journal of Affective Disorders
October 15, 2017
David Feifel, Benjamin Malcolm, Danielle Boggie et al.
Recent studies demonstrating a rapid, robust improvement in treatment resistant depression (TRD) following a single sub-anesthetic infusion of ketamine have generated much excitement. However, these studies are limited in their generalizability to the broader TRD population due to their subject exclusion criteria which typically limit psychiatric comorbidity, concurrent medication, and level of...
Molecular Psychiatry
October 3, 2017
Michelle Kokkinou, Abhishekh Hulegar Ashok, Oliver Howes
252 citations
Ketamine is a non-competitive antagonist at the N -methyl- d -aspartate receptor. It has recently been found to have antidepressant effects and is a drug of abuse, suggesting it may have dopaminergic effects. To examine the effect of ketamine on the dopamine systems, we carried out a systematic review and meta-analysis of dopamine measures in the rodent, human and primate brain following acute...
American Journal of Psychiatry
October 3, 2017
S. Wilkinson, Elizabeth D. Ballard, Michael H. Bloch et al.
680 citations
Objective Suicide is a public health crisis with limited treatment options. We conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine on suicidal ideation. Method Individual participant data were obtained from 10 of 11 identified comparison intervention studies (using either saline or midazolam as control). The analysis...
Behavioural Pharmacology
October 1, 2017
José E. Suárez-Santiago, Alfredo Briones-Aranda, Judith Espinosa-Raya et al.
Major depression is one of the most common affective disorders caused by schizophrenia. The administration of N-methyl-d-aspartate receptor antagonists, such as ketamine, can reproduce the negative and affective symptoms of this disorder in animals. Preclinical studies have shown that 5-HT6 receptor (5-HT6R) agonists and antagonists have a considerable antipsychotic response. The aim of the...
Psychopharmacology
October 2017
Jingyi Ma, L Stan Leung
Decreased GABAB receptor function is proposed to mediate some symptoms of schizophrenia. In this study, we tested the effect of CGP7930, a GABAB receptor positive allosteric modulator, on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in behaving rats. Electrodes were bilaterally implanted into the hippocampus, and cannulae were placed into the lateral...
Contemporary nurse
October 2017
Michael Neufeld, Deborah Spence, Tineke Water
Physiological risks of ketamine have been well researched, yet for health professionals (HPs) undertaking paediatric ketamine sedation, questions of benefit and harm remain. What are health care professionals' experiences of undertaking ketamine sedation with children? Hermeneutic narrative. The study comprised hermeneutic narrative analysis of stories from seven HPs in nursing, medicine,...
Journal of Psychopharmacology
October 2017
Paul Glue, Natalie J. Medlicott, Sarah Harland et al.
The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
October 2017
Chadi G. Abdallah, Christopher L. Averill, Ramiro Salas et al.
Prefrontal global brain connectivity with global signal regression (GBCr) was proposed as a robust biomarker of depression, and was associated with ketamine's mechanism of action. Here, we investigated prefrontal GBCr in treatment-resistant depression (TRD) at baseline and following treatment. Then, we conducted a set of pharmacological challenges in healthy subjects to investigate the...
Brain and nerve = Shinkei kenkyu no shinpo
October 2017
Kenji Hashimoto
Depression is often misdiagnosed as major depressive disorder in patients with bipolar disorder. Therapeutic drugs for these two disorders are quite different, but the anesthetic ketamine shows fast-acting antidepressant effects in treatment-resistant patients with these disorders. Here, we discuss biomarkers for both disorders, recent findings regarding ketamine, and predictable biomarkers for...
Journal of Psychopharmacology
October 1, 2017
Cameron Castle, Andrew Gray, Shona Neehoff et al.
20 citations
Patients receiving ketamine for refractory depression and anxiety report dissociative symptoms in the first 60 min post-dose. The most commonly used instrument to assess this is the Clinician-Administered Dissociative States Scale (CADSS), developed based on the assessment of patients with dissociative symptoms. Its psychometric properties for ketamine-induced dissociation have not been...
Journal of Affective Disorders
September 27, 2017
J. V. Vande Voort, Robert J Morgan, Simon Kung et al.
correction
We recently became aware of an error in the classification of one study subject's positive treatment response status at the end of the post-continuation phase of this study. We originally reported that all 5 subjects who achieved depressive symptom remission during the acute phase of the study (and thus received 4 weekly continuation phase ketamine infusions) were classified as responders at...
Journal of Clinical Anesthesia and Pain Management
September 22, 2017
Khidr Hassan, S El-Mallakh Rif
Depression is one of the leading causes of disability not only in the US but worldwide as well. It is ranked third for global disease burden by the WHO and estimated to affect 350 million people worldwide. The economic burden of depression is estimated to have increased by 21.5% from 2005 to 2010 (from $173.2 billion to $210.5 billion).